Insider Transactions in Q3 2024 at Alnylam Pharmaceuticals, Inc. (ALNY)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-16.96%
|
$4,200,000
$280.0 P/Share
|
|
Aug 20
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+14.5%
|
$1,275,000
$85.0 P/Share
|
|
Aug 12
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
22,025
-14.64%
|
$5,968,775
$271.83 P/Share
|
|
Aug 12
2024
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
20,725
+26.47%
|
$1,885,975
$91.36 P/Share
|
|
Aug 06
2024
|
Dennis A Ausiello Director |
SELL
Open market or private sale
|
Direct |
20,250
-46.12%
|
$5,305,500
$262.79 P/Share
|
|
Aug 06
2024
|
Dennis A Ausiello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,250
+40.16%
|
$2,389,500
$118.24 P/Share
|
|
Aug 01
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,148
-17.1%
|
$4,089,960
$270.0 P/Share
|
|
Aug 01
2024
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,148
+14.6%
|
$1,287,580
$85.0 P/Share
|
|
Jul 11
2024
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,093
-8.81%
|
$1,851,273
$261.0 P/Share
|